"Imugene’s PFS HR was comparable to the landmark Genentech/Roche registrational ToGA study
(PFS HR of 0.71), which also examined the effect of Herceptin plus chemotherapy versus SOC
chemotherapy alone in advanced HER-2 positive gastric cancer."
So the benefit is the same as Herceptin, but my understanding is that the safety / side effects of Herceptin can be nasty. Can anyone elaborate?
Ann: Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials, page-31
-
- There are more pages in this discussion • 315 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.001(2.04%) |
Mkt cap ! $357.0M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $279.2K | 5.733M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 94 | 12992150 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 1795056 | 6 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |